

Oncology Venture

Oncology Venture A/S
Venlighedsvej 1, DK-2970 Hoersholm
CVR no. DK 28 10 63 51

Interim report for the period January 1, 2020 – June 30, 2020

Contents

Statement by the Board of Directors and the Executive Board	3
Management's review	4 - 17
Consolidated income statement and statement of comprehensive income	18 - 19
Consolidated balance sheet	20 - 21
Consolidated statement of changes in equity	22
Consolidated cash flow statement	23
Parent company income statement	24
Parent company balance sheet	25 - 26
Parent company statement of changes in equity	27
Consolidated notes	28 - 34

Statement by the Board of Directors and the Executive Board

The Board of Directors and the Executive Board provide their assurance that the interim report provides a fair and true overview of the Parent Company's and the Group's operations, financial position and results, and describes material risks and uncertainties faced by the parent Company and the Group.

Hoersholm, Denmark, August 28, 2020

Executive Board

Steve Carchedi	Henrik Kristian Moltke

Board of Directors

Duncan Moore Chairman	Frank Knudsen Vice chairman	Steve Carchedi
Steen Meier Knudsen	Gunnar Magnus Severus Modée Persson	Carani Sanjeevi

CONSOLIDATED FINANCIAL HIGHLIGHTS AND RATIOS

Amounts in DKK '000	Q2 2020	Q2 2019	H1 2020	H1 2019	Year 2019
Key figures					
Profit/loss					
Revenue	0	216	0	519	801
Profit/loss before depreciation (EBITDA)	-5,231	-15,319	-22,528	-28,084	-66,502
Operating profit/loss before net financials	-5,500	-15,594	-23,060	-28,636	-148,102
Net financials	2,619	-9,984	2,837	-12,084	-26,822
Net profit/loss	-3,503	-23,181	-18,918	-36,859	-138,132
Balance sheet					
Balance sheet total	172,909	259,874	172,909	259,874	181,201
Purchase of PPE	0	40	0	40	56
Equity	143,921	182,880	143,921	182,880	141,334
Cash flows					
Cash flows from:					
Operating activities	-7,943	-21,614	-21,170	-38,149	-72,415
Investing activities	0	-5,676	0	-4,126	-3,814
Financing activities	10,422	32,194	13,557	48,483	84,760
Ratios					
Solvency ratio	83%	70%	83%	70%	78%
Earnings per share, DKK	-0.03	-0.38	-0.14	-0.65	-2.08
Diluted earnings per share, DKK	-0.03	-0.38	-0.14	-0.65	-2.08

HIGHLIGHTS DURING Q2 2020

- On April 3, the company announced a draw-down of the first tranche of SEK 10 million under its convertible note agreement with Negma Group LTD and Park Partners GP.

- On April 7, the company announced a notice to convene Annual General Meeting 2020, to be held on 22 April 2020.

- On April 17, Oncology Venture announced a directed issue of 925,925 shares under its convertible note agreement with Negma Group LTD and Park Partners GP.

- On 22 April, the company announced that it would test the activity of its PARP inhibitor, Stenoparib (formerly 2X-121), as a potential therapy for Coronavirus. The testing would be conducted by the Pathogen and Microbiome Institute at Northern Arizona University.

- On 22 April, the minutes from the Annual General Meeting 2020 was published.

- On May 6, Oncology Venture announced that the company had entered into a USD 5 million equity investment agreement with a new US based investor named Global Corporate Finance. The agreement runs for 36 months, during which time Oncology Venture can solely decide to exercise investments by GCF, sequentially, in a number of tranches.

- On May 7, the company announced a directed share issue of 1,952,475 new shares in connection with debt conversion directed to Global Corporate Finance and a consultant.

- On 29 May, Oncology Venture published its Q1 2020 report, covering the period January – March 2020.

- On 8 June, the company announced that it had acquired the remaining 37% ownership in its priority Dovitinib program from investor Sass & Larsen ApS and thereby had gained full control of the company’s Dovitinib program.

- On 9 June, Oncology Venture announced a directed issue of 751,879 shares under its convertible note agreement with Negma Group LTD and Park Partners GP.

- On 9 June, Oncology Venture calls the first investment tranche under its share subscription agreement with Global Corporate Finance.

- On 10 June, Oncology Venture announced a directed issue of 2,255,639 shares under its convertible note agreement with Negma Group LTD and Park Partners GP.

- On 11 June, the company announced the termination of the agreement with its liquidity provider Sedermera Fondkommission.

- On 10 June, the company announced a directed issue of 5,177,584 shares under its convertible note agreement with Negma Group LTD and Park Partners GP.

- On 29 June, Oncology Venture made public that it had signed an agreement to out-license two pipeline assets as part of its prioritized portfolio strategy to Smerud Medical Research International. The deal concerned the two clinical pipeline assets, LiPlaCis® and 2X-111. As a part of the terms of the deal, Oncology Venture is eligible to receive significant milestone payments as well as royalties.

- On 30 June, the company announced a directed issue of 1,574,803 shares under its convertible note agreement with Negma Group LTD and Park Partners GP.

HIGHLIGHTS AFTER THE PERIOD

- On 13 July, Oncology Venture announced that it had acquired full ownership of its PARP inhibitor (Stenoparib, formerly 2X-121) program, and thereby Oncology Venture had gained full control of all three of the Company's prioritized programs, Stenoparib, Dovitinib and Ixempra®, an important step in the execution of the Company's strategy to eliminate external ownership of its key assets and retain maximum value of its priority programs.

- On 14 July, the company announced a directed issue of 2,255,639 shares under its convertible note agreement with Negma Group LTD and Park Partners GP.

- On 18 August, the company announced a directed issue of 1,893,939 shares under its convertible note agreement with Negma Group LTD and Park Partners GP. Thereby all outstanding convertible loan notes were converted.

- On 21 August, Oncology Venture announced it has called upon the second investment tranche under its share subscription agreement with Global Corporate Finance and was issuing 5,980,020 shares at SEK 1.34 per share.

- On 21 August, Oncology Venture announced that it will offer new shares in exchange for previously annulled warrants as part of clean-up of remaining obligations incurred prior to former management departure.

- On 26 August, Oncology Venture announced that the company's novel PARP inhibitor Stenoparib had shown anti-viral activity against Coronavirus in pre-clinical studies. In addition, it was announced that based on these findings, the company planned to advance the compound into human clinical trials, and moreover an update on the studies of Stenoparib as a treatment of ovarian cancer were also communicated. Finally, the announcement also made public that Stenoparib was the new name of the drug, until then known as 2X-121.

CEO LETTER

Dear shareholders,

It has been 9 months since we announced our new commercial, focused strategy for OV, and I am happy to inform you that we have made very significant progress in executing on the strategy.
Please, allow me first to highlight the very good data we have received on 2X-121 or Stenoparib for the treatment of Covid-19. These data are so promising that we now are planning for clinical studies with Stenoparib. If everything works out as intended, this could mean that Stenoparib will become Oncology Venture's first product to reach the market given the much faster clinical development times for anti-infectives vs oncology products. Globally activity in oncology clinical trials has slowed down considerably since the onset of the pandemic. Clearly this is not the case for Covid-19 relevant projects and the public funding available is consequently also growing. The testing was done by the Pathogen and Microbiome Institute (PMI) at Northern Arizona University and showed in preclinical studies that Stenoparib has a significant in vitro anti-viral activity against Coronavirus. PMI is known for its world-class science and is currently dedicating much of its significant research capacity to fight the COVID-19 pandemic, and their research showed positive results both when applying Stenoparib as a single agent and in combination with the well-known drug Remdesivir. As I have stated several times before, my ambition is that Oncology Venture is an opportunistic company, and this promising development shows that OV is vigilant and can pursue opportunities when possible, and thereby change the financial outlook in the future.

Another significant event is the licensing of LiPlaCis and 2X-111 to Smerud Medical Research. This deal can result in milestone fees that may well amount to several hundred million Swedish kronor - followed by significant royalties when the products come to market. Strategically partnering with Smerud to take over these two projects, was fully in line with our strategy, and was one of our key priorities was to maximize the value from our portfolio.

Our efforts to make the company focused on the three high-priority projects also resulted in OV successfully gaining full control of both the 2X-121 and the Dovitinib projects. By having full control of all our three high-priority projects, OV can move much faster on the development of the assets, increases the financial value of the programs for our shareholders and improves our strategic negotiating position which is important in our discussions with larger pharmaceutical companies.

Our Dovitinib project is also progressing as planned. Our aim is still to file for approval of Dovitinib in the US as a treatment of Renal Cell Carcinoma (kidney cancer), based on non-inferiority, by the end of this year. I would also like to add that while we couldn't have hoped for any better outcome of the testing of Stenoparib as a possible treatment of Covid-19, it does not change our commitment that we remain determined to develop Stenoparib as a precision treatment for advanced ovarian cancer. As soon as we have significant news to report we will immediately publish an announcement. The same is true for our third high-priority asset Ixempra®, which is being developed as precision treatment for breast cancer patients.

Concerning our financials, we have made significant improvement in our balance sheet. You may recall that one of our goals was to lead the company toward commercialization. Part of that goal is to improve our financial position and ultimately improve our balance sheet. Today, I am proud to report some very positive news. For the first time we are delivering real operating income of a total of more than SEK 7 million, funds coming from our prudent management of our capital and recent licensing deal with Smerud Medical Research. We also see clearly that the general cost-efficiency measures are bearing fruit, as expenses have significantly been reduced when comparing to the corresponding periods in 2019. Moreover, we have been able to book notable financial income coming from the mark-to-market value of OV's shares in Lantern Pharma which is our partner for Irofulven. This revised book value of the Lantern shares follows the public NASDAQ listing of Lantern in April. OV were granted shares in Lantern Pharma when Lantern licensed Irofulven to OV in 2015. In addition, our efforts to reduce financial expenses start to become very visible in our financial reporting, as our expenses are down from more than SEK 12 million in Q2 2019 to just above SEK 1 million in Q2 2020. As a result, I am pleased to say that our current a half-year company financials for 2020 are 50 % better than compared to first half-year of 2019. This is a remarkable financial turnaround for the company in less than 9 months.

I am also pleased to report that we, in the midst of the Covid-19 pandemic, we also secured access to additional equity financing of 50 million SEK, bringing the total now total amount of funds we have secured up to 150 million SEK.

While we have more work to do, we are now at a stage where we have delivered and exceeded on all of our goals, I set out in my first CEO letter in November 2019. Today, we have continued to develop on our focused the pipeline, continue to improve our financial condition and continued to work toward commercialization to deliver increased shareholder value. At the same time, we have been opportunistic with innovative development programs such as Stenoparib to maximize the potential for financial upside for the company. Our financials are moving in the right direction on all parameters, however, better is always possible. In addition, we have also simplified the ownership of our pipeline, thereby improving the investment case of the company long term. Finally, we are less than six months from our expected Dovitinib filing, a possible major trigger of shareholder value, and possibly play a key role in solving the Covid-19 pandemic and transforming Stenoparib into a treatment for patients.

So busy times are ahead and we look forward to realizing the potential of the company. After all the patients are waiting. I believe that OV will in the near future will deliver a strong news flow that will substantiate OVs position as a dynamic and rapidly developing oncology company with a potentially game changing DRP diagnostic platform.

Steve Carchedi

President and Chief Executive Officer

ABOUT ONCOLOGY VENTURE A/S

Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics (cDx) generated by its proprietary drug response predictor technology, DRP®.

The Company has three high-priority programs: Dovitinib –a pan-tyrosine kinase inhibitor (pan-TKI), which is post Phase 3 trials, being prepared for a U.S. new drug approval (NDA) filing in renal cell carcinoma (RCC); Stenoparib, a PARP inhibitor in Phase 2 trials for treatment of ovarian cancer and in the preparation phase for advancing into clinical trials; IXEMPRA® (Ixabepilone) –an approved and marketed (U.S.) microtubule inhibitor being advanced for Phase 2 clinical development (in the EU) for the treatment of breast cancer. In addition, the company's pipeline includes LiPlaCis® (licensed to Smerud Medical Research), a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer; 2X-111 (licensed to Smerud Medical Research), a liposomal formulation of doxorubicin staged for Phase 2 trials in metastatic breast cancer and glioblastoma (primary brain cancer); and Irofulven, a DNA damaging agent, in Phase 2 for prostate cancer.

Drug Response Predictor (DRP®) Platform

Oncology Venture's proprietary and best-in-class DRP® predictive biomarker technology enables us to identify and treat those patients who are sensitive to a particular cancer drug candidate. DRP® provides a gene expression fingerprint that distinguishes the tumor forms that are sensitive to treatment with a specific drug from those who are insensitive. By including only patients with sensitive tumors in clinical trials, it is possible to avoid also treating non-sensitive patients, which lowers drug efficacy read-outs. The important bottom line is that the DRP® technology has demonstrated, in 29 out of 37 clinical trials, that clinical results of cancer treatments can be predicted with a high degree of statistical significance.



The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in an advanced systems biology analytic algorithm. DRP® is based on messenger RNA from the patient's biopsies. The DRP® platform (both the drug-specific DRP® biomarkers and the PRP® patient guidance reports), can be used in all cancer types and is patented for more than 70 anti-cancer drugs in the US. The PRP® is in development for potential future commercialization within the Personalized Medicine market sector.

Patient Response Prediction (PRP®)

Long term, the DRP® technology will be the base of the development of Patient Response Predictor (PRP®) products in the oncology sector. Collections of drug-specific DRP® biomarkers can be included in a single PRP® patient guidance report to assist the patient and their oncologist with valuable input on potential therapy options. We believe that PRP® can become a powerful tool for a large group of cancer patients where other biomarkers are currently unavailable. PRP® is a novel product opportunity within Personalized Medicine, focusing on the future development of consumer products and services to inform, gather and formulate personal treatments together with the consultation and care of an oncologist. The PRP® report makes it possible to assist patients and doctors by helping them determine which cancer treatment may be most suitable in each specific case.

DEVELOPMENT PROJECTS

Oncology Venture has a pipeline of six drug development projects, with Dovitinib (a pan-TKI), Stenoparib (formerly 2X-121, a PARP inhibitor), and IXEMPRA® (Ixabepilone) having the highest priority. Two projects, LiPlaCis® and 2X-111, are licensed Smerud Medical Research International.

Stenoparib (2X-121)

Stenoparib is a novel small molecule (oral), targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in cancer cells, currently being evaluated for cancer and Corona virus.

Stenoparib as a potential antiviral therapy for treating COVID-19

Stenoparib has shown in vitro anti-viral activity against Coronavirus in pre-clinical studies conducted at the Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease test center. Based on these findings, Oncology Venture plans to advance the compound into human clinical trials as a potential therapy for COVID-19.

The series of pre-clinical studies indicated that Stenoparib showed inhibitory activity against Coronavirus in LLC-MK2 cells as a single agent. In addition, Stenoparib in combination with remdesivir was active in inhibiting SARS-Cov-2, the virus that causes COVID-19, in VERO E6 cells. The concentration of Stenoparib required for virus inhibition was lower in the combination study than in the single agent study. The two drugs target the virus through unique but different mechanisms of action. Remdesivir blocks the RNA replication enzyme, while Stenoparib, as an inhibitor of PARP1/PARP2 (Poly ADP-Ribose Polymerases) and tankyrase 1 and 2 inhibits virus assembly and inhibits the negative effects of virus infection on the human body such as cytokine storm and necrosis.

Oncology Venture is optimistic that the tankyrase activity may confer an advantage on the company's molecule vs other PARP inhibitors which do not exhibit dual PARP/tankyrase inhibitory activity.

Stenoparib as a cancer therapeutic

Stenoparib is currently being evaluated for the treatment of advanced ovarian cancer in a DRP®-guided Phase 2 clinical trial at the Dana-Farber Cancer Institute (Boston, MA U.S.A.) using a DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome. The drug has been tested in over 60 patients to date and is demonstrated to be safe and well tolerated. Through use of DRP® patient selection, OV aims to provide a superior clinical benefit, to ovarian cancer patients receiving Stenoparib, as compared to other approved PARP inhibitors.

Following temporary new patient enrollment delays results from the ongoing Coronavirus pandemic, the Company expects enrollment to restart in its Phase 2 ovarian cancer trial for Stenoparib at the Dana-Farber Cancer Institute (Boston, MA U.S.A.) by late Q4 2020. Thus far, 10 of a target 30 patients are enrolled in the study.

The Company is opening a second trial site, at Guy's Hospital (London, UK) to accelerate patient accrual to the trial. Guy's Hospital was the site of the prior Phase 1 study of Stenoparib under sponsorship by Eisai. The IRAS (IRB) submission is ongoing.

During the second quarter of 2020, the company decided to focus resources and efforts on the clinical advancement in ovarian cancer and Covid-19, and therefore the Phase 2 study (Denmark) of Stenoparib in heavily pretreated breast cancer (mBC) patients, that was initiated in 2018, would be terminated. The current data from that mBC trial suggest that a diagnostic biopsy cannot be used for predicting likelihood of drug response in heavily pretreated mBC patients, and instead new biopsies are needed.

The global PARP inhibitor market is projected to reach USD 9 billion by 2027 in ovarian cancer alone.

Dovitinib

Dovitinib is Oncology Venture's most advanced clinical asset. Following a pre-NDA meeting, the U.S. FDA has provided guidance to the company regarding its potential path to approval. Based on this feedback from the FDA, Oncology Venture now plans to file a New Drug Application (NDA) for the approval of Dovitinib for the treatment of RCC late in the second half of 2020.

Oncology Venture will seek U.S. approval for Dovitinib based on "non-inferiority" against the already approved compound Sorafenib (Bayer) for the treatment of RCC, based on prior Phase 3 trial results (by Novartis). Oncology Venture will use the data from the prior Phase 3 trial to prove that Dovitinib is in fact "non-inferior" to Sorafenib for the treatment of RCC, and expects that Dovitinib will be approved by the FDA as a safe and efficacious drug beneficial to RCC patients as a

third line treatment. It is important to note that the review process is unpredictable and may or may not lead to a formal approval.

Dovitinib is a small molecule, pan-tyrosine kinase inhibitor (TKI) licensed from Novartis, that was previously developed through Phase 3 clinical trials. This extensive drug development program includes data from more than 2,500 patients. Dovitinib has shown identical clinical activity to Sorafenib (NEXAVAR®, an approved pan-TKI marketed by Bayer) in a randomized Phase 3 study in renal cancer and in a randomized Phase 2 study in liver cancer, both conducted by Novartis. Sorafenib is the current gold standard in the treatment of certain forms of liver cancer and approved in certain forms of renal cancer. Dovitinib has also shown activity in several Phase 2 studies in lung, prostate, endometrial and thyroid cancers, as well as GIST.

Oncology Venture has previously, successfully validated its DRP® for Dovitinib using clinical biopsy materials for most of Novartis' prior clinical trials for the drug. Accordingly, future development of Dovitinib will benefit from use of the drug-specific DRP® to identify the patients who will most likely benefit. DRP® has shown a strong ability to predict treatment response in prior clinical studies of renal, endometrial, GIST, liver and breast cancer tumors.

Dovitinib addresses a significant unmet need for new treatments for Renal Cell Carcinoma. Annual sales of Sorafenib, under the trade name NEXAVAR®, were approximately USD 715 million in 2018. The global Renal Cell Carcinoma market is projected to grow to USD 6.3 billon 2022. Additionally, Dovitinib has promising market potential, both as a monotherapy and in combination with other agents (such as immune checkpoint inhibitors) in a number of other cancer indications.

IXEMPRA® (Ixabepilone)

Oncology Venture holds an exclusive option to license the European rights to IXEMPRA®(ixabepilone) from the pharmaceutical company R-Pharm U.S. The drug was originally developed by Bristol-Myers Squibb (BMS) and is approved in the U.S. for the treatment of certain types of breast cancer. The Company is currently advancing a protocol to evaluate IXEMPRA® for the treatment of metastatic breast cancer in a DRP®-guided Phase 2 clinical trial, with multiple sites planned in Europe. The Company's protocol aims towards an enrollment target of nearly 40 patients. Through use of DRP® patient selection, OV aims to provide a superior clinical benefit to breast cancer patients receiving IXEMPRA® compared to other approved therapy options. Enrollment of patients is planned to begin during Q3 2020; however, because of the COVID-19 pandemic and last-minute changes at the hospital clinical trial sites it may not be possible to meet the planned schedule.

The global breast cancer therapeutics market is projected to grow to USD $25 Billion by 2024. One of the leading drivers of this market growth will be the use of pre-surgery neoadjuvant therapies in the newly diagnosed patient population, a future market expansion opportunity for IXEMPRA®.

Shareholders

The table below shows shareholders with over 5% of the votes and capital in Oncology Venture A/S on August 15, 2020.

Shareholderbase as of 15 August 2020		
Name:	Number of shares	Percentage of voting rigths and capital (%)
SASS & LARSEN APS	36.860.251	19,8%
UBS SWITZERLAND AG,	11.109.477	6,0%
Others	137.804.603	74,2%
Total numbers of shares	185.774.331	100,0%
Total number of shareholders	7.731	

The share

On August 15, 2020, the share capital totaled DKK 9,288,717, distributed between 185,774,331 shares with a quotient value of DKK 0,05. There is only one class of stock. Each share carries one vote at the Annual General Meeting and all shares carry equal right to a share in the assets and profits of the Company. In the period January 1 to August 15, 2020, the share price decreased from SEK 1.7 to SEK 1.42. At end of the period, the market capitalization was SEK 263.8 million, based on a closing price of SEK 1.42. During the period 538,334,024 Oncology Venture shares were traded for a value of SEK 1,247,196,184.

Warrants

As an incentive for the board members, employees, key persons and investors, Oncology Venture A/S has implemented a total of five warrant programs, of which four are active:

Warrant plan #6
On October 18, 2019 an equity-settled stock option plan was approved at an extraordinary general meeting, which provides board of directors and members of the executive management of the Group with the option to purchase ordinary shares of Oncology Venture A/S at a fixed price. Warrants were granted with a monthly vesting of 1/36 until October 1, 2022, provided that the individuals concerned remain within the Group's employment. Vested warrants are exercisable over a fixed period of time from grant date, up to and including September 30, 2032.

Warrant plan #5
On February 24, 2017 an equity-settled stock option plan was approved at an extraordinary general meeting, which provides the board of directors and members of the executive management of the Group with the option to purchase ordinary shares of Oncology Venture A/S at a fixed price. Warrants were granted either immediately vesting upon the grant, or with a monthly vesting of 1/36 until July 1, 2019, provided the individuals remain within the Group's employment. Vested warrants are exercisable over a fixed period of time from grant date up to and including July 1, 2021.

Warrant plan #4
On February 18, 2016, the board of directors approved an equity-settled stock option plan, which provides key management personnel with the option to purchase ordinary shares of Oncology Venture A/S at a fixed price. Warrants were granted with a monthly vesting of 1/36 from July 1, 2016 until July 1, 2019, provided the holders remain within the Group's employment. Vested warrants are exercisable over a fixed period of time from grant date, up to and including July 1, 2021.

Warrant plan #3
On December 17, 2014, the board of directors approved an equity-settled stock option plan, which provides key management personnel and with the option to purchase ordinary shares of Oncology Venture A/S at a fixed price. Warrants was granted with 50% immediately vesting upon granting, 25% vesting on December 17, 2015 and 25% vesting on July 3, 2016, provided they remain within the Group's employment. Vested warrants are exercisable over a fixed period of time from grant date up to and including July 1, 2021.

Investor warrants

50,341,080 investor warrants (TO2 warrants) have been granted to investors in connection with subscription of Offer Units in the rights issued carried out from October–December 2019. All warrants were vested as per the grant date. A warrant gives the right, during a fixed period, to subscribe for nominal DKK 0.05 ordinary share in the Company at SEK 6,0 (the "Exercise Price"),

converted into DKK using the official exchange rate between DKK and SEK on the exercise day. Each warrant carries the right to subscribe. Investors in the Rights Issue will have the possibility to exercise their warrants in five two-week windows during the 24-month period during which the warrants may be exercised.

These periods are: April 1, 2020–April 15, 2020, September 1, 2020–September 15, 2020, February 1, 2021–February 15, 2021, May 1, 2021–May 15, 2021 and September 1, 2021–September 15, 2021

Operational risks and uncertainties

The risks and uncertainties that the Company is exposed to are related to factors such as drug development, competition, technology development, patents, regulatory requirements, capital requirements, currencies and interest rates. During the current period, no significant changes in risk factors or uncertainties have occurred. For a more detailed description of these risks and uncertainties, refer to the prospectus published in October 2019. The document is available on the Company's website (http://www.oncologyventure.com).

Auditor´s review

The interim report has not been reviewed by The Company's auditor.

For further information, please contact

Henrik Moltke, CFO
E-mail: hm@oncologyventure.com
Cell Phone: (+45) 53 63 9637
Website: www.oncologyventure.com

Certified Advisor

Oncology Venture's Certified Adviser is:
Svensk Kapitalmarknadsgranskning AB
Fähusgatan 5
603 72 Norrköping, Sweden
Phone: +46 11-32 30 732.

FINANCIAL REVIEW

Income statement Q2 2020

The Company had a net loss of minus 3.4 million DKK in the second quarter of 2020. In the second quarter of 2019 the loss was 23.2 million DKK. The improvement of the net result is due to four main changes: A reduction of the Company's obligations in the LiPlacis and 2X-111 programs, which were out licensed to Smerud, of 7.1 million DKK. A reduction of 3.2 million DKK in the cost base, from 15.5 million DKK in second quarter 2019 to 12.3 million DKK in second quarter 2020. A revised book value of the Company share position in Lantern Pharma, as Lantern Pharma went public in June 2020 and Oncology Venture could, by 30 June 2020, book a value of 3.4 million DKK. Compared to the second quarter of 2019 that equals an increase of the Company's financial income of 1.0 million DKK. The financial expenses were reduced from 12.7 million DKK in the second quarter of 2019 to 1.0 million DKK in the second quarter of 2020. This change is reflecting the change of strategy, not to establish expensive short-term loans to fund the Company's activities.

Measured on the first six months of 2020, the Company had a net loss of 18.9 million DKK compared to 36.9 million DKK in H1 2019, an almost 50 % reduction.

Balance sheet

The balance sheet as of 30 June 2020 was 172.9 million DKK compared to 259.9 million DKK in same period 2019. The difference is mainly due to the impairment test of the value of company's development projects at year 2019, leading to a lower book value of the total pipeline.

Cash flows

The Company's cash position at 30 June 2020 was 2.6 million DKK compared to 7,8 million DKK as of 30 June 2019.

Significant financial events during Q2 2020

Oncology Venture 6 May 2020 announced that is has secured a US $5 million (50 million SEK) investment and entered into a share subscription agreement with Global Corporate Finance (GCF). GCF is a private family office that invests in both public and private companies across the globe.
The main conditions and structure of the financing agreement are:

- The agreement runs for 36 months, during which time Oncology Venture can solely decide to exercise investments by GCF in multiple tranches of up to 10 million SEK each against issuing Company shares to GCF.

- The share subscription price in each tranche shall be calculated as 95% of the daily volume weighted average price (VWAP) of the Company's shares for the five (5) consecutive trading days following the date of a draw-down notice from OV.

- The financing costs for Oncology Venture are five percent (5%) of the total commitment of US $5 million (SEK 50 million), excluding legal and administrative costs.

Oncology Venture announced 29 June 2020 that it has signed a definitive agreement out-licensing two clinical pipeline assets, LiPlaCis® and 2X-111, to Smerud Medical Research International for further clinical and commercial development. Under the terms of the agreement, OV may receive regulatory milestone fees of nearly US $30M plus royalties on sales. OV also terminated its prior license agreement with Cadila Pharmaceuticals for the development of LiPlaCis® in India.
Smerud Medical Research International AS ("SMERUD") is a leading European-based clinical contract research organization (CRO) with expertise in the development of precision cancer drugs. SMERUD has previously worked with OV on its LiPlaCis® program as well as several other clinical programs. Under their new agreement, SMERUD will advance the specific development of LiPlaCis® in late stage metastatic breast cancer and 2X-111 in glioblastoma multiforme, in connection with each program's DRP® companion diagnostic.

Capital resources and Liquidity

The Company has access to liquidity through convertible notes and directed rights issues of 150 million SEK. Combining these sources of funding will bring the Group well into 2021. Management is continuously evaluating a variety of partnering agreements and asset sales to optimize funding costs.

Financial Calendar

Financial Calendar year ends on December 31, 2020
Interim Report January-September is expected to be published on November 30, 2020.

Consolidated income statement and statement of comprehensive income

Note	Amounts in DKK '000	Q2 2020	Q2 2019	H1 2020	H1 2019	Year 2019
4	**Revenue**	**0**	**216**	**0**	**519**	**801**
5	Other operating income	7,099	0	7,099	0	2,100
	Other external expenses	-6,230	-10,996	-17,424	-20,801	-46,821
	Staff expenses, share-based payments	-1,002	-28	-2,333	-100	-2,210
	Staff expenses, other	-5,098	-4,511	-9,870	-7,702	-20,372
	Loss before depreciation and amortisation (EBITDA)	**-5,231**	**-15,319**	**-22,528**	**-28,084**	**-66,502**
	Depreciation and amortisation	-269	-275	-532	-552	-81,600
	Operating loss before net financials	**-5,500**	**-15,594**	**-23,060**	**-28,636**	**-148,102**
	Financial income	3,661	2,722	4,224	3,010	3,281
	Financial expenses	-1,042	-12,706	-1,387	-15,094	-30,103
	Profit/loss before tax	**-2,881**	**-25,578**	**-20,223**	**-40,720**	**-174,924**
	Tax on profit/loss	-622	2,397	1,305	3,861	36,792
	Net profit/loss	**-3,503**	**-23,181**	**-18,918**	**-36,859**	**-138,132**
	Other comprehensive income to be reclassified to profit or loss in subsequent periods (net of tax):					
	Exchange differences on translation of foreign operations	103	-18	36	50	119
	Other comprehensive income, net of tax	**103**	**-18**	**36**	**50**	**119**
	Total comprehensive income	**-3,400**	**-23,199**	**-18,882**	**-36,809**	**-138,013**

Consolidated income statement and statement of comprehensive income

Note	Amounts in DKK '000	Q2 2020	Q2 2019	H1 2020	H1 2019	Year 2019
	Net profit/loss attributable to:					
	Owners of the parent company	-3,394	-22,931	-18,814	-36,132	-131,955
	Non-controlling interests	-109	-250	-104	-727	-6,177
	Total	**-3,503**	**-23,181**	**-18,918**	**-36,859**	**-138,132**
	Total comprehensive income attributable to:					
	Owners of the parent company	-3,291	-22,949	-18,778	-36,082	-131,836
	Non-controlling interests	-109	-250	-104	-727	-6,177
	Total	**-3,400**	**-23,199**	**-18,882**	**-36,809**	**-138,013**
6	**Earnings per share**					
	Earnings per share, DKK	-0.03	-0.38	-0.14	-0.65	-2.08
	Diluted earnings per share, DKK	-0.03	-0.38	-0.14	-0.65	-2.08

Consolidated balance sheet

ASSETS

Note	Amounts in DKK '000	30/06/2020	30/06/2019	31/12/2019
7	Property, plant and equipment	2,514	3,322	2,917
8	Acquired patents	826	1,083	955
8	Development projects in progress	155,023	235,849	155,023
	Other investments	3,702	0	0
	Total non-current assets	**162,065**	**240,254**	**158,895**
	Trade receivables	0	216	637
	Income tax receivable	1,179	9,418	5,512
	Other receivables	3,458	1,580	5,300
	Prepayments	3,608	604	681
	Cash	2,599	7,802	10,176
	Total current assets	**10,844**	**19,620**	**22,306**
	Total assets	**172,909**	**259,874**	**181,201**

Consolidated balance sheet

EQUITY AND LIABILITIES

Note	Amounts in DKK '000	30/06/2020	30/06/2019	31/12/2019
	Share capital	8,462	3,524	6,067
	Share premium	353,077	255,521	310,527
	Retained earnings	-221,249	-99,256	-192,970
	Currency translation reserve	276	171	240
	Non-controling interests	3,355	22,920	17,470
	Total equity	**143,921**	**182,880**	**141,334**
	Lease liabilities	1,953	2,567	2,274
	Deferred tax	6,096	34,234	6,096
	Non-current liabilities	**8,049**	**36,801**	**8,370**
	Convertible loan	3,906	0	0
	Loan	0	21,198	3,578
	Bank debt	584	710	0
	Lease liabilities	614	532	573
	Trade payables	11,317	14,541	14,537
	Other payables	4,518	3,212	286
	Deferred income	0	0	12,523
	Current liabilities	**20,939**	**40,193**	**31,497**
	Total liabilities	**28,988**	**76,994**	**39,867**
	Total equity and liabilities	**172,909**	**259,874**	**181,201**

Consolidated statement of changes in equity

Amounts in DKK '000	Share capital	Share premium	Retained earnings	Currency translation reserve	Non-controlling interest	Total equity
Equity as at 01/01/2020	6,067	310,527	-192,970	240	17,470	141,334
Profit/loss			-18,814		-104	-18,918
Other comprehensive income				36		36
Total comprehensive income	0	0	-18,814	36	-104	-18,882
Cash capital increase in Q1	466	7,079				7,545
Cash capital increase in Q2	259	5,238				5,497
Capital increase, debt conversion in Q2	373	6,967				7,340
Capital increase, acquisition of NCI in Q2	1,297	24,510				25,807
Costs of capital increases		-1,244				-1,244
Acquisition, non-controlling interests			-11,798		-14,011	-25,809
Share-based payments			2,333			2,333
Equity as at 30/06/2020	**8,462**	**353,077**	**-221,249**	**276**	**3,355**	**143,921**
Equity as at 01/01/2019	2,516	213,554	-61,040	121	26,705	181,856
Profit/loss			-36,132		-727	-36,859
Other comprehensive income				50		50
Total comprehensive income	0	0	-36,132	50	-727	-36,809
Cash capital increase, including issue of warrants	764	43,114				43,878
Capital increase, debt conversion, including issue of warrants	244	13,267				13,511
Costs of capital increase		-14,414				-14,414
Acquisition, non-controlling interests			-2,250		-3,058	-5,308
Share-based payments			166			166
Equity as at 30/06/2019	**3,524**	**255,521**	**-99,256**	**171**	**22,920**	**182,880**

Consolidated cash flow statement

Amounts in DKK '000	Q2 2020	Q2 2019	H1 2020	H1 2019	Year 2019
Loss before tax	**-2,881**	**-25,578**	**-20,223**	**-40,720**	**-174,924**
Adjustment for non-cash items	1,271	321	2,865	718	83,875
Financial income, reversed	-3,661	-2,722	-4,224	-3,010	-3,281
Financial expenses, reversed	1,042	12,706	1,387	15,094	30,103
Change in working capital	-9,085	6,192	-6,722	4,630	9,716
Cash flows from operating activities before net financials	**-13,314**	**-9,081**	**-26,917**	**-23,288**	**-54,511**
Financial income received	134	233	666	276	53
Financial expenses paid	-102	-12,744	-271	-15,094	-26,899
Income tax received	5,485	0	5,498	0	8,942
Income tax paid	-146	-22	-146	-43	0
Cash flows from operating activities	**-7,943**	**-21,614**	**-21,170**	**-38,149**	**-72,415**
Purchase of property, plant and equipment	0	-40	0	-40	-56
Purchase of intangible assets	0	-328	0	-328	0
Acquisition of non-controlling interests	0	-5,308	0	-5,308	-5,308
Sale of investments in associates	0	0	0	1,550	1,550
Cash flows from investing activities	**0**	**-5,676**	**0**	**-4,126**	**-3,814**
Cash capital increase	3,323	43,878	10,868	43,878	92,251
Transaction cost, capital increase	-189	-2,818	-904	-2,818	-29,536
Proceeds from loan	6,854	17,601	6,854	33,347	57,739
Repayment of loan	-11	-26,392	-3,567	-26,392	-35,199
Bank debt	584	10	584	710	0
Lease liabilities	-139	-85	-278	-242	-495
Cash flows from financing activities	**10,422**	**32,194**	**13,557**	**48,483**	**84,760**
Total cash flows	**2,479**	**4,904**	**-7,613**	**6,208**	**8,531**
Cash, beginning	7	2,916	10,176	1,547	1,547
Net foreign exchange difference	113	-18	36	47	98
Cash, end	**2,599**	**7,802**	**2,599**	**7,802**	**10,176**

Parent company income statement

Amounts in DKK '000	Q2 2020	Q2 2019	H1 2020	H1 2019	Year 2019
Revenue	**0**	**862**	**0**	**1,802**	**3,718**
Other operating income	-2,100	0	-2,100	0	2,100
Other external expenses	-4,213	-4,962	-6,912	-8,217	-16,900
Staff expenses	-3,672	-2,284	-7,756	-3,535	-13,270
Profit/loss before depreciation, amortization and impairment (EBITDA)	**-9,985**	**-6,384**	**-16,768**	**-9,950**	**-24,352**
Amortization and depreciation	-164	-168	-324	-337	-676
Impairment losses					-233,875
Operating profit/loss before net financials	**-10,149**	**-6,552**	**-17,092**	**-10,287**	**-258,903**
Financial income	3,554	2,911	4,004	3,439	3,992
Financial expenses	-1,144	-13,840	-1,327	-17,272	-30,541
Profit/loss before tax	**-7,739**	**-17,481**	**-14,415**	**-24,120**	**-285,452**
Tax on profit/loss	441	649	620	864	3,037
Net profit/loss	**-7,298**	**-16,832**	**-13,795**	**-23,256**	**-282,415**

Parent company balance sheet

ASSETS

Amounts in DKK '000	30/06/2020	30/06/2019	31/12/2019
Acquired patents	132	539	336
Development projects in progress	1,123	1,332	1,228
Intangible assets	**1,255**	**1,871**	**1,564**
Plant and machinery	55	86	71
Property, plant and equipment	**55**	**86**	**71**
Investment in subsidiaries	29,785	82,835	3,978
Other investments	3,702	0	0
Receivables from subsidiaries	0	135,219	163
Financial assets	**33,487**	**218,054**	**4,141**
Total fixed assets	**34,797**	**220,011**	**5,776**
Receivables from subsidiaries	1,016	142	0
Trade receivables	0	216	637
Income tax receivable	470	2,565	2,170
Other receivables	2,717	1,531	3,390
Prepayments	3,607	445	201
Cash and cash equivalents	1,956	7,602	4,548
Total current assets	**9,766**	**12,501**	**10,946**
Total assets	**44,563**	**232,512**	**16,722**

Parent company balance sheet

EQUITY AND LIABILITIES

Amounts in DKK '000	30/06/2020	30/06/2019	31/12/2019
Share capital	8,462	3,524	6,067
Share premium	353,077	255,521	310,527
Retained earnings	-332,139	-59,185	-318,344
Total equity	**29,400**	**199,860**	**-1,750**
Payables to subsidiaries	2,593	2,938	2,658
Bank debt	584	710	0
Convertible loan	3,906	0	0
Loan	0	21,198	3,578
Trade payables	6,104	6,954	6,013
Income tax payable	0	0	286
Other payables	1,976	852	5,937
Current liabilities	**15,163**	**32,652**	**18,472**
Total liabilities	**15,163**	**32,652**	**18,472**
Total equity and liabilities	**44,563**	**232,512**	**16,722**

Parent company statement of changes in equity

Amounts in DKK '000	Share capital	Share premium	Retained earnings	Total equity
Equity as at 01/01/2020	6,067	310,527	-318,344	-1,750
Cash capital increase in Q1	466	7,079		7,545
Cash capital increase in Q2	259	5,238		5,497
Capital increase, debt conversion in Q2	373	6,967		7,340
Capital increase, acquisition of NCI in Q2	1,297	24,510		25,807
Costs of capital increases		-1,244		-1,244
Profit/loss			-13,795	-13,795
Equity as at 30/06/2020	**8,462**	**353,077**	**-332,139**	**29,400**
Equity as at 01/01/2019	2,516	213,554	-35,929	180,141
Cash capital increase, including issue of warrants	764	43,114		43,878
Capital increase, debt conversion, including issue of warrants	244	13,267		13,511
Costs of capital increases		-14,414		-14,414
Profit/loss			-23,256	-23,256
Equity as at 30/06/2019	**3,524**	**255,521**	**-59,185**	**199,860**

Consolidated notes

1. Accounting policies
2. Significant accounting estimates and assessments
3. Segment information
4. Revenue
5. Other financial income
6. Earnings per share
7. Property, plant and equipment
8. Intangible assets
9. Contingent liabilities
10. Related parties
11. Events after the balance sheet date

1. Accounting policies

Basis of preparation

This interim report comprises financial information about the Group and the parent company.

The interim consolidated financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union. The parent company financial statements have been prepared in accordance with the Danish Financial Statements Act.

The interim financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the annual report for 2019.

New accounting policy

The Group has implemented the latest amendments to International Financial Reporting Standards effective as of 1 January 2020 as adopted by the European Union. None of the amendments have had any material impact on the Group's financial statements.

Convertible loan

Convertible loan facility has been separated into liability and equity components based on the terms of the contract. On issuance of the convertible loan facility, the fair value of the liability component, is determined using a market rate for an equivalent non-convertible instrument.

The transaction costs are allocated to each component of the loan.

2. Significant accounting estimates and assessments

In connection with the preparation of the Condensed consolidated interim financial statements, the management makes a number of accounting estimates and assessments that affect the recognized values of assets, liabilities, income, expenses and cash flows as well as their presentation.

The significant accounting estimates and assessments applied in these Condensed consolidated interim financial statements are the same as disclosed in note 0 and note 2 in the annual report for 2019, which contains a full description of significant accounting estimates and assessments.

3. Segment information

Oncology Venture A/S is still at an early commercial phase with a limited revenue generating activities. Accordingly, Oncology Venture A/S only has one operating segment, which is also the only reportable segment. Information on profit/loss and total assets for the segment can be found in the interim consolidated income statement and the interim consolidated statement of financial position.

Amounts in DKK '000	Q2 2020	Q2 2019	H1 2020	H1 2019	Year 2019
4. Revenue					
Revenue is distributed as follows:					
Rendering of services	0	216	0	519	801
Total	0	216	0	519	801
5. Other operating income					
Income from licenses	7,000	0	7,000	0	0
Grants	99	0	99	0	2,100
Total	7,099	0	7,099	0	2,100

Amounts in DKK '000	Q2 2020	Q2 2019	H1 2020	H1 2019	Year 2019
6. Earnings per share					
Earnings per share (basic)					
Profit/loss attributable to the owners of the parent company	-3,394	-22,931	-18,814	-36,132	-131,955
Average number of shares in circulation	130,973,961	60,505,192	132,665,515	55,436,395	63,407,230
Earnings per share, DKK	-0.03	-0.38	-0.14	-0.65	-2.08
Diluted earnings per share					
Diluted average number of shares in circulation	130,973,961	60,505,192	132,665,515	55,436,395	63,407,230
Diluted earnings per share, DKK	-0.03	-0.38	-0.14	-0.65	-2.08

No dilution where the warrants are anti-dilutive.

Amounts in DKK '000	Plant and machinery	Right-of-use asset	Total
7. Property, plant and equipment			
Cost as at 01/01/2020	2,185	3,341	5,526
Cost as at 30/06/2020	2,185	3,341	5,526
Depreciation and impairment losses as at 01/01/2020	1,941	668	2,609
Depreciation	69	334	403
Depreciation and impairment losses as at 30/06/2020	2,010	1,002	3,012
Carrying amount as at 30/06/2020	**175**	**2,339**	**2,514**
Cost as at 01/01/2019	2,129	0	2,129
Adoption of IFRS 16	0	3,341	3,341
Additions	40	0	40
Disposals	0	0	0
Cost as at 30/06/2019	2,169	3,341	5,510
Depreciation and impairment losses as at 01/01/2019	1,766	0	1,766
Depreciation	88	334	422
Depreciation and impairment losses as at 30/06/2019	1,854	334	2,188
Carrying amount as at 30/06/2019	**315**	**3,007**	**3,322**

Amounts in DKK '000	Acquired patents	Develop-ment projects in progress	Total
8. Intangible assets			
Cost as at 01/01/2020	1,324	235,521	236,845
Additions	0	0	0
Cost as at 30/06/2020	1,324	235,521	236,845
Amortisation and impairment losses as at 01/01/2020	369	80,498	80,867
Amortisation	129	0	129
Amortisation and impairment losses as at 30/06/2020	498	80,498	80,996
Carrying amount as at 30/06/2020	**826**	**155,023**	**155,849**
Cost as at 01/01/2019	1,324	235,521	236,845
Additions	0	328	328
Cost as at 30/06/2019	1,324	235,849	237,173
Amortisation and impairment losses as at 01/01/2019	112	0	112
Amortisation	129	0	129
Amortisation and impairment losses as at 30/06/2019	241	0	241
Carrying amount as at 30/06/2019	**1,083**	**235,849**	**236,932**

Amounts in DKK '000	30/06/2020	30/06/2019	31/12/2019
Individually material development projects in progress			
LiPlaCis	58,851	58,851	58,851
2X-111	0	39,759	0
2X-121	40,863	40,863	40,863
Dovitinib	55,309	55,309	55,309
Irofulven	0	40,739	0
Other	0	328	0
Total	155,023	235,849	155,023

Remaining amortization period

All intangible assets above are development projects in progress.

9. Contingent liabilities

There have been no significant changes in the commitments and contingencies as described in note 23 to the annual report for 2019.

10. Related parties

Transactions with related parties

Amounts in DKK '000		Sales to related parties	Purchases from related parties	Amounts owed by related parties	Amounts owed to related parties
Services provided	Q1-Q2 2020		506		0
	Q1-Q2 2019		1,322		0

11. Events after the balance sheet date

No significant events have occurred after the end of the financial period.